$CANB is directly recognized in this feature about
Post# of 42560
From the article:
https://www.marketwatch.com/press-release/exp...re_twitter
Motley Fool sees that there will be a lot of M&A activity building off of 2020. They said the sector as hot again, coming off of two large deals. They said: "In the past few months, some big deals have taken place in the cannabis industry. In December 2020, there was news of a near-$4 billion merger including Canadian pot giants Aphria and Tilray, which will create the largest cannabis company in the world in terms of revenue. Earlier this month, Jazz Pharmaceuticals also announced it would be acquiring GW Pharmaceuticals. And with more states legalizing marijuana and a slightly more pot-friendly presidential administration and U.S. Congress in place, there’s tons of excitement in the industry right now.... It’s not uncommon for cannabis companies to acquire other businesses. In the U.S. pot market, where pot is illegal at the federal level and can’t cross state lines, it has become a necessary form of expansion. One of Curaleaf’s largest acquisitions was the purchase of Grassroots last year for $875 million, which increased the number of states it operated in from 18 to 23."
CAN B CORP. (OTCQB: CANB) BREAKING NEWS:Can B Corp. Acquires Assets from Leading-Edge Hemp Technology Group – Can B Corp. ("Can B" or the "Company" , a diversified health and wellness company, is pleased to announce it has closed on the acquisition of assets and talent from a hemp derivative development and manufacturing group. A newly formed wholly-owned subsidiary, Botanical Biotech LLC (“BB”), will be the new home for Florida-based research & development laboratory and extraction facility for the Company. BB will focus on developing and implementing new pharmacokinetics technology and partnering with global and emerging brands to create innovative products and solutions that are positioned for sustainability and wellness and are culturally driven.
The new subsidiary will be led by President Bradley Lebsock. BB will aim to improve upon what Mother Nature has given us by using cutting-edge science to develop innovations that offer a greater value proposition by optimizing the formulation of plant-based products to improve the bio-availability of bio- active compounds and ensure long-term stability to ensure the consumer has a consistent experience. There are several strategies that can be used to enhance the liberation, solubilization, and absorption of bio-active compounds. BB’s extensive experience utilizing these pharmaceutical homogenization techniques allowing us to manipulate molecules and offer scalable cost-effective formulations paired with the ability to articulate the unique value propositions of a formula through our in-house marketing and communications team.
B&B’s team are at the forefront of hemp isolate extraction into CBG, CBN, and other cannabinoids found in the hemp plant. According to a February 2020 Healthline Media report, “CBD and CBG are both non-intoxicating cannabinoids, meaning they won’t make you high, and both interact with the same receptors in the body, according to a 2018 study Trusted Source, and appear to have anti-inflammatory effects”. The article goes on to name a plethora of possible additional benefits of the CBG and CBN cannabinoids.
Visit our Video Center
Marco Alfonsi, Can B’s Chief Executive Officer, commented, “We are thrilled to bring Brad’s team under our umbrella and leverage their scientific approach to our current and future developed products. Their product development and science-based technology and innovations will benefit our proprietary brands and Pure Health Products production facility in WA. We look forward to working more closely with Brad and his team at Can B Corp.” For more information on CANB, please visit: https://www.canbcorp.com/investors/